We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.39 | -0.43% | 91.23 | 91.00 | 91.62 | 91.72 | 89.63 | 91.38 | 1,682,358 | 16:40:00 |
From Apr 2019 to Apr 2024
By Allison Prang
The European Medicines Agency's Committee for Medicinal Products for Human Use is recommending that approval for an atopic dermatitis treatment from Regeneron Pharmaceuticals Inc. and Sanofi be extended, the companies said Friday.
The committee is recommending that the European Union approval be extended to also include people with moderate-to-severe cases of this type of dermatitis who are systemic therapy candidates and between ages 12 and 17, the companies said.
They said they expect the European Commission's final decision on the treatment's application should come in the coming months.
Write to Allison Prang at allison.prang@wsj.com
(END) Dow Jones Newswires
June 28, 2019 07:48 ET (11:48 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
